Scientific deep-dive
Semaglutide and Days Spent in Hospital
A prespecified analysis of SELECT found hospital days falling from 176.2 to 157.2 per 100 patient-years. It is a modest number from a randomized trial, which is what makes it trustworthy.
Cardiovascular trials report hazard ratios for events most people will never have. A prespecified analysis of the SELECT trial measured something more recognizable: how much time participants spent in hospital. Semaglutide cut it from 176.2 to 157.2 days per 100 patient-years.[1]
What was measured
SELECT randomized 17,604 people with obesity and established cardiovascular disease but without diabetes. We covered its main result, fewer major cardiovascular events, in the evidence-duration article. This analysis asked a different question of the same trial.
| Measure | Semaglutide | Placebo | Rate ratio |
|---|---|---|---|
| Any indication | 157.2 | 176.2 | 0.89 (95% CI 0.82–0.98), p=0.01 |
| Serious adverse events | 137.6 | 153.9 | 0.89 (95% CI 0.81–0.98), p=0.02 |
No heterogeneity appeared across BMI, age or sex subgroups. The reduction was consistent rather than concentrated in one group.[1]
Why days in hospital is a better unit
A hazard ratio for a composite cardiovascular endpoint is hard to feel. Days in hospital is not. It captures severity as well as frequency, since a long admission counts for more than a short one. And it adds up everything that put someone in a bed, not only the events a trial was designed to count.
The cohort had a high rate of hospital admissions to begin with. That is what makes an 11% relative reduction worth stating in days.
It is also the outcome that translates most directly into cost, which is usually argued about separately from clinical benefit. Here one number covers both: time in hospital is expensive for health systems and disruptive for people.
What kind of evidence this is
The analysis was prespecified and exploratory, and the two words mean different things. Prespecified means the analysis was planned before the data were seen, so it is not a result someone went looking for afterward. Exploratory means it was not the endpoint the trial was powered to answer, so it should be read as supportive rather than definitive.
What it has that most hospitalization findings do not is randomization. We have covered several observational studies reporting fewer hospitalizations on these drugs, in people with cancer and in infection risk. Every one of them carries the objection that healthier people get prescribed newer drugs. Randomization removes that objection.
Frequently Asked Questions
References
- 1.Nicholls SJ, Ryan DH, Deanfield J, et al. Semaglutide and Hospitalizations in Patients With Obesity and Established Cardiovascular Disease: An Exploratory Analysis of the SELECT Randomized Clinical Trial JAMA Cardiology. 2026. PMID: 41433034.
Compare the sellers
Rankings
Seller reviews
Related research
GLP-1 Drugs and Blood Pressure: How Much It Falls, and What Happens When You Stop
On the FDA labels, systolic blood pressure fell about 4 to 7 points more than placebo on tirzepatide and 3 to 5 on semaglutide. 24-hour monitoring confirmed it, weight loss explained most of it, and in the withdrawal trials much of it came back.
8 min read
GLP-1s and Atrial Fibrillation: Reading a 42% Headline
A meta-analysis of ten trials in 12,651 patients found a 42% lower risk of new atrial fibrillation on semaglutide. None of those trials was designed to measure it, and the absolute numbers were never published.
6 min read
Two Studies, One Comparison, Two Answers
One real-world study found no cardiovascular difference between the two drugs. Another found semaglutide 29% better. Working out why they disagree is more useful than either answer.
6 min read
Semaglutide and Peripheral Artery Disease: The Label, the Options and Coverage
STRIDE showed semaglutide 1 mg improved walking distance in type 2 diabetes with PAD, and Novo Nordisk filed for a US label change in 2025. Ozempic's label still lists no PAD use, but PAD already counts as cardiovascular disease on the Ozempic and Wegovy labels.
7 min read
The Statistic That Asks If Groups Differ
A SOUL secondary analysis found oral semaglutide cutting heart-failure events in people who had heart failure and doing nothing in those who did not. The test of whether that split is real came out at P = .06.
7 min read
The Head-to-Head, and What It Settles
751 adults randomized to tirzepatide or semaglutide, each at maximum tolerated dose, for 72 weeks. Tirzepatide produced 20.2% weight loss against 13.7%, and on several other endpoints the answer runs the other way.
7 min read
Where to get semaglutide online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Collective
From $59/mo + membership
Get started →Luvo Health
Moving between compounded and brand without changing seller
From $179/mo
Get started →Embody
From $79/mo
Get started →